These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21610153)

  • 21. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
    Marinov M; Ziogas A; Pardo OE; Tan LT; Dhillon T; Mauri FA; Lane HA; Lemoine NR; Zangemeister-Wittke U; Seckl MJ; Arcaro A
    Clin Cancer Res; 2009 Feb; 15(4):1277-87. PubMed ID: 19228731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
    Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
    Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
    Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM; Turchi JJ
    Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
    Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
    J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
    Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
    PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma.
    Kapoor V; Zaharieva MM; Das SN; Berger MR
    Cancer Lett; 2012 Jun; 319(1):39-48. PubMed ID: 22202640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
    Liu N; Tai S; Ding B; Thor RK; Bhuta S; Sun Y; Huang J
    Endocr Relat Cancer; 2012 Oct; 19(5):711-23. PubMed ID: 22919067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
    Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
    Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway.
    Hung CM; Lin YC; Liu LC; Kuo SC; Ho CT; Way TD
    Chem Biol Interact; 2016 Dec; 260():1-12. PubMed ID: 27769712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
    Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A
    Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
    Márk Á
    Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
    Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
    J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules.
    Zhang XQ; Ding YW; Chen JJ; Xiao X; Zhang W; Zhou L; Kong QW; Shi MZ; Yang J; Jiang B; Guo C; Han YL
    J Ethnopharmacol; 2020 Oct; 261():113067. PubMed ID: 32505840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential susceptibility to etoposide in clones derived from a human ovarian cancer cell line.
    Balan KV; Sitaras NM; Dimas K; Han Z; Wyche JH; Pantazis P
    Chemotherapy; 2006; 52(3):137-46. PubMed ID: 16645270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.